Clinical Microbiomics at ECCMID 2023

Our team was attending the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) this week in Copenhagen.

Thank you to everyone who visited our booth during the conference. We enjoyed discussing with you all on how our metagenomics and metabolomics analysis solutions can support infectious disease clinical studies.

Big congrats and a special thank you to Joshua Claypool, Senior Scientist at Rebiotix Inc. (a Ferring Company), who gave a presentation on significant and durable microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent C. difficile infection. We are very proud to have supported Rebiotix’s engraftment analysis for this trial.

At Clinical Microbiomics, we offer microbiome and metabolome analysis services for:
• Including microbiome endpoints in your phase 1, 2, 3 clinical trials
• Guiding your development of novel antibiotic treatments
• Analyzing levels of antimicrobial resistance genes

At Clinical Microbiomics, we believe that our inner ecology – that delicate microbial ecosystem known as the microbiome – is the new frontier in human health. We exist to untangle its complexity and explore its potential to tackle the most pressing health questions of our time.

Operating as an extension of the research organizations of the world’s most prominent academic institutions and leading biotech, consumer health and pharma companies, we support clients throughout the entire study – from study planning to the final report.

We are looking forward to seeing you all again next year in Barcelona!

In case you missed us at this years event, or if you would like to learn more about our microbiome research services, contact us.

Get in touch

Tell us about your study.

Please enable JavaScript in your browser to complete this form.